Found 127 clinical trials
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not
- 326 views
- 08 Nov, 2020
- 27 locations
Efficacy and Safety of Olaparib Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)
This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with Fluorouracil (5-FU) in participants with unresectable or metastatic
- 10 views
- 21 Jun, 2021
- 115 locations
Investigating Safety Tolerability Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours
A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.
- 16 views
- 02 Jun, 2021
- 20 locations
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes
At present targeted therapy with the PARP inhibitor olaparib has become standard of care in advanced platinum sensitive BRCA1/2 mutant ovarian cancer. The key in this sensitivity is the loss of
- 0 views
- 25 Jan, 2021
- 1 location
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab Followed by Maintenance Durvalumab Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.
bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
- 84 views
- 20 Jun, 2021
- 288 locations
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have
- 135 views
- 20 Jun, 2021
- 147 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
be nine cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort
- 0 views
- 10 Jun, 2021
- 12 locations
Olaparib for PAH: a Multicenter Clinical Trial
can reverse PAH in several animal models1. Interestingly, PARP1 inhibition is also cardioprotective. Olaparib, an orally available PARP1 inhibitor, can reverse cancer growth in animals and humans with
- 4 views
- 24 Jan, 2021
- 4 locations
Paclitaxel Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously treated advanced Gastric Cancer (GC).
- 0 views
- 12 Apr, 2021
- 1 location
Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus
The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer who are unsuitable for
- 2 views
- 08 Nov, 2020